Biotechnology · Healthcare
Peggy Scherle
Equibles does not estimate personal net worth.
Get an email with a short summary when Prelude Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get PRLD alertsAbout Peggy Scherle
The proxy statement of Prelude Therapeutics Inc reports total compensation of $819,729 for Peggy Scherle in fiscal 2025, including a base salary of $473,416. Disclosed compensation is on record for 4 fiscal years. Peggy Scherle has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Prelude Therapeutics Inc on October 20, 2026. Prelude Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Prelude Therapeutics Inc includes Krishna Vaddi (CEO and Board Member), Bryant D. Lim (CFO), Julian C. Baker (Board Member) and 3 others.
Peggy Scherle on recent calls
“So with the CAT6 biology, it's pretty clear that CAT6A is amplified in ER-positive breast cancer. And being amplified and overexpressed, it really drives the whole estrogen signaling biology as well as MYC regulation. and cell cycle genes, so it really has a strong role in driving breast cancer growth and survival.”
“Today, I wanted to summarize our efforts that led to the successful discovery of our first-in-class oral CAT-6A selective degrader and highlight how this is a differentiated approach to maximize the benefits of a clinically validated target in ER-positive breast cancer.”
Affiliation history
-
Prelude Therapeutics Inc (PRLD)
Proxy statement
CurrentStart not stated–present
Last confirmed April 29, 2026
Company network
Leadership on record at Prelude Therapeutics Inc
- Krishna Vaddi CEO, Board Member
- Bryant D. Lim CFO
- Julian C. Baker Board Member
- Katina Dorton Board Member
- Martin Babler Board Member
- Paul Scherer, M.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Prelude Therapeutics Inc (PRLD) | Ph. D. Chief Scientific Officer | $473,416 | $819,729 |
| 2022 | Prelude Therapeutics Inc (PRLD) | Chief Scientific Officer | $416,667 | $1,630,482 |
| 2021 | Prelude Therapeutics Inc (PRLD) | Chief Scientific Officer | $408,271 | $2,641,799 |
| 2020 | Prelude Therapeutics Inc (PRLD) | Chief Scientific Officer | $347,865 | $2,690,241 |